Remove 2030 Remove Sativa Remove Sleep
article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

To IGC’s knowledge, this is the first human clinical trial using low doses of natural THC, a psychoactive member of the cannabinoid class of natural products produced by the Cannabis sativa plant, on Alzheimer’s patients. As the disease progresses, individuals may suffer from loss of memory and dementia.